GALWAY, Ireland--(BUSINESS WIRE)--4Tech Inc., which is developing the world’s first transcatheter device, TriCinch™, for repair of the Tricuspid heart valve, announced today that it has appointed Hardip Thakerar as Global Vice President of Therapy Development. In this position, Hardip will be responsible for overseeing all sites enrolling patients in the 4Tech “Prevent” clinical trial, as well as identifying and training new sites in Europe, and globally.
